<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01331993</url>
  </required_header>
  <id_info>
    <org_study_id>D1120C00030</org_study_id>
    <nct_id>NCT01331993</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study to Compare VIMOVO Manufactured at AstraZenca AB to VIMOVO Manufactured by Patheon Pharmaceuticals and Marketed Enteric-coated Naproxen Formulation</brief_title>
  <official_title>A Phase I, Open-label, Randomised, 3-way Crossover Study to Demonstrate Bioequivalence of a Single Oral Dose of Naproxen Administered as VIMOVO Manufactured at AstraZeneca AB Compared to That of VIMOVO Manufactured by Patheon Pharmaceuticals and a Marketed Enteric-coated Naproxen Formulation (Manufactured by Roche) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose is to demonstrate the bioequivalence of naproxen administered as VIMOVO
      manufactured at a new facility in Sweden (AstraZeneca) to that of naproxen administered as
      VIMOVO manufactured in the USA (Patheon) and to a marketed enteric-coated naproxen
      formulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Open-label, Randomised, 3-way Crossover Study to demonstrate Bioequivalence of a
      Single Oral Dose of Naproxen administered as VIMOVO manufactured at AstraZeneca AB compared
      to that of VIMOVO manufactured by Patheon Pharmaceuticals and a marketed enteric-coated
      Naproxen Formulation (Manufactured by Roche) in Healthy Volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in area under the plasma concentration-time curve (AUC) from time zero to infinity</measure>
    <time_frame>Pre-dose to Day 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Adverse Events as a measure of Safety and Tolerability</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Adverse Events as a measure of Safety and Tolerability</measure>
    <time_frame>Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Adverse Events as a measure of Safety and Tolerability</measure>
    <time_frame>Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Adverse Events as a measure of Safety and Tolerability</measure>
    <time_frame>Day 4</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment order : A, B, C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment order : B, C, A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment order : C, A, B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment order : A, C, B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment order : B, A, C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment order : C, B, A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIMOVO (AstraZeneca)</intervention_name>
    <description>VIMOVO (AstraZeneca) 500 mg naproxen/20 mg esomeprazole</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <other_name>Treatment A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIMOVO (Patheon)</intervention_name>
    <description>VIMOVO (Patheon) 500 mg naproxen/20 mg esomeprazole</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <other_name>Treatment B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marketed enteric-coated naproxen formulation</intervention_name>
    <description>Marketed enteric-coated naproxen formulation (manufactured by Roche) 500 mg tablet</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <other_name>Treatment C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female volunteer, aged 18 - 55 years (inclusive)

          -  Female volunteers must be non-pregnant and non-lactating and have a negative urine
             pregnancy test result prior to enrolment into the study.

          -  Female volunteers of childbearing potential must be using appropriate birth control
             during the entire duration of the study

          -  Body mass index of = 19 to =30 kg/m2 (inclusive) and weights of = 50 to = 100 kg
             (inclusive)

        Exclusion Criteria:

          -  Volunteer who is likely to have unrecognized cardiovascular or cerebrovascular
             disease, based on history or risk factors, or who has a clinical significant ECG
             finding at screening

          -  Uncontrolled hypertension defined as resting systolic pressure &gt;140 mmHg or diastolic
             pressure &gt;90 mmHg at screening or admission to Period 1

          -  Presence or prior history of abnormal bleeding or bleeding disorders, or any volunteer
             with significant history of peptic ulcer disease or other acid related
             gastrointestinal symptoms

          -  Any gastrointestinal disease, abnormality or gastric surgery that may interfere with
             gastric emptying, motility and drug absorption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stepehn Kanes</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca, Wilmington, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kingsley Urakpo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Drug Research Unit at Guy's Hospital, 6 Newcomen St, London SE1 1YR, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2011</study_first_submitted>
  <study_first_submitted_qc>April 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2011</study_first_posted>
  <last_update_submitted>October 17, 2011</last_update_submitted>
  <last_update_submitted_qc>October 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>crossover</keyword>
  <keyword>bioequivalence</keyword>
  <keyword>naproxen</keyword>
  <keyword>esomeprazole</keyword>
  <keyword>vimovo</keyword>
  <keyword>healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

